OTLKW - Outlook Therapeutics® to Present at the Retina World Congress 2024 | Benzinga
ISELIN, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced it will present at the 2024 Retina World Congress being held May 9-12, 2024 in Fort Lauderdale, FL.
Details for the presentations are as follows:
Session: Retina Unplugged
Panelist: Russell Trenary, President and Chief Executive Officer
Date and Time: Thursday, May 9, 2024 at 8:10 AM ET
As part of the panel, Mr. Trenary will discuss Outlook Therapeutics' ONS-5010/LYTENAVA™, an investigational ophthalmic ...